Evidence map›Paper›PMID 42077386›Full record

ArticleEuropean heart journal. Digital health2026

Artificial intelligence-enhanced electrocardiogram for the detection of rheumatic heart disease.

Raeesa Bhorat, David M Harmon, Kan Liu, Jennifer Dugan, Christie Ngo, Paul A Friedman, Herman Bagula, Mpiko Ntsekhe, Zachi I Attia

Abstract read
In one paragraph

Article in European heart journal. Digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raeesa BhoratDivision of Cardiology, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
David M HarmonDepartment of Cardiovascular Medicine, Mayo Clinic, 200 1st ST SW Rochester, Rochester, MN, USA.ORCID https://orcid.org/0000-0002-8102-3380
Kan LiuDepartment of Cardiovascular Medicine, Mayo Clinic, 200 1st ST SW Rochester, Rochester, MN, USA.
Jennifer DuganDepartment of Cardiovascular Medicine, Mayo Clinic, 200 1st ST SW Rochester, Rochester, MN, USA.
Christie NgoDepartment of Cardiovascular Medicine, Mayo Clinic, 200 1st ST SW Rochester, Rochester, MN, USA.
Paul A FriedmanDepartment of Cardiovascular Medicine, Mayo Clinic, 200 1st ST SW Rochester, Rochester, MN, USA.
Herman BagulaDivision of Cardiology, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
Mpiko NtsekheDivision of Cardiology, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-0851-7675
Zachi I AttiaDepartment of Cardiovascular Medicine, Mayo Clinic, 200 1st ST SW Rochester, Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Rheumatic heart disease (RHD) remains the most prevalent acquired cardiovascular disease among young adults in developing countries, and there is a critical need for an efficient, affordable, and available screening strategy to detect RHD in these resource-limited areas. The 12-lead electrocardiogram (ECG) is a ubiquitous, inexpensive diagnostic tool, and application of artificial intelligence to the ECG (AI-ECG) has allowed for screening of various cardiovascular pathologies. Methods and results: Patients aged >18 years with severe RHD with at least one transthoracic echocardiogram and one standard 12-lead ECG performed at Groote Schuur Hospital, Cape Town, within 180 days of each other were eligible. A total of 920 RHD patients were identified, with 2199 corresponding controls from the same medical centre. Patients were allocated to derivation (80%), validation (10%), and testing (10%) groups, respectively. The AI-ECG to detect RHD from a standard 12-lead ECG was built using the Keras framework under Tensorflow backend. In the test group, the AI-ECG for RHD exhibited strong algorithm performance with an AUC of 0.890 (95% Confidence Interval 0.848-0.940) and an accuracy of 83.8%. The algorithm remained robust between RHD presentation: mitral valve alone (AUC 0.913) and mixed mitral and aortic valve disease (AUC 0.858). There were minor performance differences in the subgroup analysis of patient sex, age, and ECG characteristics. Conclusion: In this study, an AI-ECG algorithm was successfully developed to screen for advanced RHD from a standard 12-lead ECG, and the AI-ECG performance remained acceptable across most subgroups, including RHD manifestation, patient sex, age <70 years, and ECG characteristics.

Indexed as

Artificial intelligenceElectrocardiogramNeural networkrheumatic heart disease

Identifiers

PMID42077386
PMCPMC13131984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.